On October 31, 2023 Alligator Bioscience (Nasdaq Stockholm: ATORX) reported that it will hold a Capital Markets Day on December 1, 2023 (Press release, Alligator Bioscience, OCT 31, 2023, View Source [SID1234636512]). The event will be hosted by members of Alligator’s executive management team who will provide an overview of the Company’s strategy, its prorietary and partnered assets, and its technology platforms.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Capital Markets Day Details
Date/Time: Friday, December 1, 2023 at 2:00 PM CET / 8:00 AM EST
Location: 7A Posthuset, Vasagatan 28, Stockholm, Sweden
Format: In-person event to be streamed live
To attend the event in person, contact IR & Communications Manager, Greta Eklund, at [email protected]. Please note that the number of seats is limited.
The event will be live-streamed to Alligator’s Youtube channel, accessible through this link.
Capital Markets Day Agenda
Overview of Alligator Bioscience: Chief Executive Officer Søren Bregenholt will present an overview of the Company’s strategic direction and its prorietary and partnered assets
Lead Asset Mitazalimab: Chief Medical Officer Dr. Sumeet Ambarkhane will provide an update on the clinical data generated so far by mitazalimab along with a broader view of the Company’s CD40 program
Key Opinon Leader: Dr. Gregory Beatty, Associate Professor of Medicine at the University of Pennsylvania, will explain the current treatment landscape for pancreatic cancer and the potential of mitazalimab to change the treatment paradigm
Alligator’s Technology Platforms: Chief Technology Officer Laura von Schantz will discuss Alligator’s proprietary technology platforms Neo-X-Prime and Ruby, including the pivotal role Ruby is playing in Alligator’s research collaboration and license agreement with Orion Corporation
ATOR-4066: Chief Scientific Officer Peter Ellmark will look at the progress Alligator is making with ATOR-4066, a third generation bispecific antibody targeting CD40 and CEACAM5, developed by the Company’s Neo-X-Prime platform
4-1BB: Chief Medical Officer Dr. Sumeet Ambarkhane will provide the latest updates on ATOR-1017, Alligator’s 4-1BB monoclonal antibody with best-in-class potential, and ALG.APV-527, a bispecific antibody with a tumor-directed 4-1BB agonistic effect being co-developed with Aptevo Therapeutics
Live question and answer sessions will be held after each presentation and CEO Søren Bregenholt will provide concluding remarks and present Alligator’s strategic outlook at the end of the event.